INTRODUCTION
Rectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is an increasingly prevalent disease in Taiwan. 1 Although ideal treatment recommendations for rectal cancer are still being developed, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is now considered the standard treatment for locally advanced rectal cancer (LARC). Randomised trials have demonstrated that neoadjuvant CCRT significantly improves local control and reduces toxicity profiles, compared with adjuvant CCRT in LARC. [2] [3] [4] Another advantage of neoadjuvant CCRT is that it may allow some patients to undergo sphincterpreserving surgery. 5 Even though the outcomes using this approach are encouraging, 5-year rates of local and distant recurrence range from 6% to 9% and 33% to 36%, respectively. [2] [3] [4] Furthermore, the incidence of sphincter preservation following CCRT in such patients also varies, ranging from 39% to 94%. [5] [6] [7] To further improve the clinical outcomes for rectal cancer patients treated with CCRT, the development of potential therapeutic targets is highly desirable.
The mammalian fibroblast growth factor (FGF) family comprises 18 ligands which exert their actions through four highly conserved transmembrane tyrosine kinase receptors, including fibroblast growth factor receptor (FGFR) 1, FGFR2, FGFR3 and FGFR4. FGFs and their receptors control a multitude of cellular processes in different contexts, including proliferation, differentiation, survival and motility. As such, this FGF/FGFR system is susceptible to aberration in cancer cells and deregulation of FGFR signalling pathway has been shown to play a critical role in many cancers. 8 For example, FGFR1 mutations and amplifications have been implicated in glioblastoma, 9 prostate, 10 breast 11 and lung cancers, 12 whereas aberrant FGFR2 expression has been observed in endometrial cancer, 13 breast cancer, 14 gastric cancer, 15 lung cancer 16 and melanoma. 17 Furthermore, activating mutations and overexpression of FGFR3 have been reported in bladder cancers 18 and multiple myeloma. 19 Recently, alterations of the FGFR signalling pathway in malignancies have been under the spotlight because of their high incidence rate and therapeutic potential.
Aberrations of the FGFR signalling pathway, including FGFR2, FGFR3 and FGFR4, have been demonstrated in colorectal cancers (CRCs); nevertheless, their clinical impact on therapeutic response and prognosis of rectal cancer patients treated with CCRT have not yet been elucidated. In this study, we analysed the FGFR signalling pathway in one published transcriptome of rectal cancers and identified that upregulated FGFR2 gene was correlated to the response to CCRT. The clinical implications of FGFR2 expression were further validated by studying a well-defined cohort of 172 rectal cancers treated with neoadjuvant CCRT followed by surgery.
PATIENTS AND METHODS Analysis of published transcriptomic datasets
To identify the genes critical in the response to CCRT, we reappraised the transcriptome dataset of tissues from rectal cancers deposited in the Gene Expression Omnibus. The raw files of Affymetrix HUMAN Genome U133 Plus 2.0 microarray platform were imported into Nexus Expression 3 software (BioDiscovery) to analyse all probe sets without preselection. Comparative analysis and functional profiling were performed to identify significant expressed genes, with special attention to the regulation of FGFR signalling pathway activity. Detailed information is provided in the online supplementary materials.
Patient eligibility and follow-up
The procurement of formalin-fixed tissue of rectal cancer patients was approved by the institutional review board of Chi-Mei Medical Center (IRB 10302-014). We retrieved a total of 172 rectal cancer patients with available paraffin-embedded tissue blocks between 1998 and 2004. The pretreatment (Pre-Tx) staging was assessed by using rectal endoscopic ultrasound and abdominopelvic CT scan in all 172 patients. Preoperatively, radiation therapy was given to all patients at a total dose of 45 Gy in 25 fractions over a period of 5 weeks with 24 h continuous infusion of 5-fluorouracil concurrently. Detailed information is provided in the online supplementary materials.
Histopathological evaluation of tumour specimens
Two independent pathologists who had not been informed of the patients' clinical information reappraised these tumour specimens. Post-treatment (Post-Tx) T and N stages of all patients were documented according to the 7th American Joint Committee on Cancer (AJCC) staging system. 20 Detailed Figure 1 Analysis of FGFR2 expression in responders versus non-responders to concurrent chemoradiotherapy (CCRT) in a published transcriptomic dataset of rectal cancers. In the clustering analysis of genes associated with regulation of the FGFR signalling pathway activity, FGFR2 was significantly upregulated in responders to CCRT. Tissue specimens from non-responders (blue lines) and responders (yellow lines) are indicated on top of the heatmap, and expression levels of upregulated and downregulated genes are expressed as a series of brightness of red and green colours, respectively, with those unaltered in mRNA expression coded as black. FGFR, fibroblast growth factor receptor. information of tumour regression grade (TRG), 21 22 used as an endpoint for evaluation of tumour response after neoadjuvant CCRT, is provided in the online supplementary materials.
FGFR2 immunohistochemistry and scoring
Tissue sections of rectal tumour biopsies taken before treatment were cut onto precoated slides from paraffin-embedded tissue blocks. The detail experimental protocols are provided in the online supplementary materials. The level of FGFR2 expression was assessed using H-scores, defined as the following equation: H-score=ΣPi (i+1), where i is the intensity of the stained tumour cells (0 to 3+), and Pi is the percentage of stained tumour cells with various intensities. 23 Tumours with H-scores greater than the median of all scored cases were classified as high FGFR2 expression.
Statistical analysis
The SPSS V.14 software package was used for statistical analyses. We compared FGFR2 expression status among the subgroups with various clinicopathological parameters using the χ 2 test. Local recurrence-free survival (LRFS), metastasis-free survival (MeFS) and disease-specific survival (DSS), calculated from the date of operation to the date of event, were endpoints analysed in this study. Detailed information is provided in the online supplementary materials.
RESULTS

Upregulation of FGFR2 gene predicting non-responder of CCRT
From the dataset of 46 rectal cancer cases in the public transcriptome GSE35452, we focused on 27 probes covering five genes associated with regulation of FGFR signalling pathway activity. In non-responders to CCRT, only FGFR2 displayed significantly upregulated mRNA expression ( p<0.01, figure 1, see online supplementary table S1). Based on this finding, we further characterised the expression status and clinical relevance of FGFR2 in our validation cohort of rectal cancers.
Validation of FGFR2 expression and its associations with clinicopathological features
To further investigate clinical correlations between the expression of FGFR2 and rectal cancers treated with CCRT, we used immunohistochemical staining to examine the expression of FGFR2 in clinical specimens. In addition, the consistency between FGFR2 immunoexpression using monoclonal antibodies (BIOCARE MEDICAL, Walnut Creek, California, USA) and mRNA expressions was validated in CRC cells (see online supplementary figure S1). FGFR2 immunoexpression, detected on cellular membranes and cytoplasm, was successfully scored in all 172 cases with a wide range of H-scores, varying from 105 to 320 (figure 2). As shown in table 1, high expression of FGFR2 was correlated with advanced Pre-Tx tumour ( p=0.02), Pre-Tx nodal ( p=0.02), Post-Tx tumour ( p<0.001) and Post-Tx nodal status ( p=0.004), respectively. Furthermore, high expression of FGFR2 was positively correlated with the inferior TRG, meaning inferior response to CCRT 21 22 ( p<0.001, figure 2 ). These results suggest that FGFR2 expression potentially has a role in promoting aggressive phenotypes in rectal cancers.
High expression of FGFR2 predicting shorter survivals in rectal cancer
To determine the correlation between FGFR2 expression and the prognoses of rectal cancer patients receiving CCRT, we analysed survival curves using the Kaplan-Meier method. The mean follow-up period for these patients was 48.2 months (range 6.2-131.2). Pre-Tx nodal status, Post-Tx tumour status, vascular invasion and TRG (figure 2) were predictive of at least one of the three endpoints of this study according to log-rank tests (table 2) . Of note, high FGFR2 expressing rectal cancers were characterised by a more aggressive clinical course, with significantly shorter DSS (p<0.0001; figure 3) , LRFS (p=0.001; figure 3 ) and MeFS ( p=0.0003; figure 3) . Using the Cox proportional hazards model (see online supplementary table S2), high expression of FGFR2 remained an independent prognostic factor for both DSS ( p=0.0004, HR=4.99) and MeFS (p=0.002, HR=5.38). These results indicate a negative correlation between high expression of FGFR2 and survival of rectal cancer patients receiving neoadjuvant CCRT.
DISCUSSION
Although neoadjuvant CCRT followed by surgery has become the standard treatment for LARC patients, approximately 40% of these patients inevitably experience recurrences, 2-4 leaving substantial room for improvement in survival outcomes among such patients. As cancers are in part genetic diseases, identifying genetic biomarkers with potential to predict treatment response is critical in modern cancer therapy. FGFRs are expressed in many different cell types and regulate vital cell phenotypes, making the FGFR signalling pathway susceptible to subversion by cancer cells. 8 In this study, using a published transcriptome of rectal cancers, we first identified that upregulation of FGFR2 gene within the FGFR signalling pathway was a significant candidate for predicting non-responders to CCRT. Furthermore, in our validation cohort, we demonstrated for the first time that high expression of FGFR2 predicted poor response and shorter survivals in rectal cancer patients who received neoadjuvant CCRT. These findings may contribute a new avenue for clinical management of LARC since therapeutic targeting of FGFRs is a major area of drug development.
FGFRs consist of four members, named FGFR1, FGFR2, FGFR3 and FGFR4, and all are single transmembrane receptors, containing extracellular, transmembrane and intracellular domains. Several types of genetic alterations that drive an oncogenic function for FGFRs have been recognised, including gene amplifications, activating mutations, chromosomal translocations, single nucleotide polymorphisms and aberrant splicing at the post-transcriptional level. 8 Gene amplification or activating mutations of FGFR2 have been reported in endometrial cancer, breast cancer, gastric cancer, lung cancer and melanoma. [13] [14] [15] [16] [17] In FGFR2, structural variants generated by numerous alternative gene splicing events are also important modes for regulating FGFR2 functions. In more than 20 alternative splicing variants of FGFR2 that have been identified, FGFR2 IIIb and IIIc are major splicing events. 24 25 FGFR2 has been found to be highly expressed in CRCs and correlated with tumour growth, invasion and angiogenesis. 26 27 Stronger FGFR2 expression has been observed in the invasive front of CRC cells than in the surface or central area of the cancerous cells. 27 Furthermore, decreased expression of FGFR2 in CRC cells, using short hairpin RNA, has been proven to be associated with inhibited cell migration, invasion, and tumour growth in vitro and in vivo. 27 These results are comparable with the positive correlation between advanced tumour stage and high expression of FGFR2 found in this study, meaning aggressive phenotypes may be attributed to FGFR2 expression in rectal cancers.
The FGFR signalling pathway can promote cancer development and the aggressive phenotypes conferred by aberrant FGFR expression are mainly modulated through the mitogenactivated protein kinases and phosphoinositide-3-kinase pathways. 8 Since the FGF/FGFR signalling pathway has been shown to play a fundamental role in embryogenesis, angiogenesis and wound healing, it is also implicated as having an oncogenic role in tumour neoangiogenesis. [28] [29] [30] Furthermore, the cross-talk between FGF/FGFR signalling and these oncogenic pathways could explain emerging data that indicate a role for FGF/FGFR in mediating resistance to cancer therapies 31 as well as the clinical outcomes of CCRT for rectal cancers in this study. Further validation of the interaction between these cellular pathways could also promote the development of feasible therapeutic strategies designed to overcome resistance to cancer treatments.
Several kinds of molecular-targeted therapies that focus on the FGFs and FGFR signalling pathway have been developed and most agents are small molecule tyrosine kinase inhibitors. A small molecule, Ki23057, which inhibits autophosphorylation of FGFR2 IIIb, has been reported to decrease the growth of CRC cells in vitro and in vivo.
32 Several multiple-receptor tyrosine kinase inhibitors that could target FGFRs, such as ponatinib, TSU68 and brivanib alaninate, have also been demonstrated to inhibit CRC cell growth. [33] [34] [35] [36] Recently, bevacizumab, a humanised monoclonal antibody inhibiting vascular endothelial growth factor A, has been shown to have clinical benefits in metastatic CRC patients. Interestingly, the combination of S49076, a novel FGFRs inhibitor, with bevacizumab has been proven to lead to inhibition of tumour growth in colon cancer xenograft models. 37 Furthermore, several developing antibodies targeting FGFR may have substantial benefit, as they can be used to treat cancer cells that are reliant on a particular FGFR and therefore reduce the potential toxicity of 'off-target effect.' A recent study has also demonstrated that monoclonal antibodies to FGFR2 successfully inhibit the growth of colon cancer xenograft models. 38 Further clinical trials to integrate these pharmaceutical therapies that target the FGFR signalling pathway in rectal cancer patients are urgently warranted.
In conclusion, this is the first time that high expression of FGFR2 has been shown to be significantly correlated with poor response to neoadjuvant CCRT in rectal cancers, including advanced Post-Tx tumour and nodal status and lower grade TRG. More importantly, high expression of FGFR2 represents a significant indicator of worse prognosis, especially DSS and MeFS, in rectal cancer patients receiving CCRT. Basic research has clearly demonstrated the effectiveness of FGFR2-targeting therapy for CRC both in vitro and in vivo. Therefore, treatment strategies that combine CCRT with anti-FGFR2 therapies are of potential benefit for LARC patients. Using the log-rank test, high expression of FGFR2 predicted shorter disease-specific survival (A), local recurrence-free survival (B) and metastasis-free survival (C). FGFR, fibroblast growth factor receptor.
